aTyr Pharma Gets $10M In Venture Debt

San Diego-based aTyr Pharma, a developer of protein-based therapeutics, said today that it has raised $10M in a debt financing round. The funding came from Silicon Valley Bank. According to the company, the new funding will go towards clinical development of its first therapeutic program, which is aimed at treatments of rare autoimmune diseases and a rare disease pipeline in immune disorders. Specific details of the terms of that venture debt were not announced by the company. aTyr Pharma is led by John Medlein.